CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

2.

Yi

S

,

Yan

Y

,

Jin

M

, et al.

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma

.

J Clin Invest

.

2022

;

132

(

3

):

e153283

.

3.

Prevodnik

VK

,

Lavrenčak

J

,

Horvat

M

,

Novakovič

BJ

.

The predictive significance of CD20 expression in B-cell lymphomas

.

Diagn Pathol

.

2011

;

6

(

1

):

33

.

4.

Tessoulin

B

,

Papin

A

,

Gomez-Bougie

P

, et al.

BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker

.

Front Oncol

.

2018

;

8

:

645

.

5.

Chang

BY

,

Francesco

M

,

De Rooij

MF

, et al.

Egress of CD19+ CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

.

Blood

.

2013

;

122

(

14

):

2412

-

2424

.

6.

Davids

MS

,

Roberts

AW

,

Seymour

JF

, et al.

Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma

.

J Clin Oncol

.

2017

;

35

(

8

):

826

-

833

.

7.

Wang

ML

,

Rule

S

,

Martin

P

, et al.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

.

N Engl J Med

.

2013

;

369

(

6

):

507

-

516

.

8.

Le Gouill

S

,

Thieblemont

C

,

Oberic

L

, et al.

Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma

.

N Engl J Med

.

2017

;

377

(

13

):

1250

-

1260

.

9.

Wang

ML

,

Jurczak

W

,

Jerkeman

M

, et al.

Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma

.

N Engl J Med

.

2022

;

386

(

26

):

2482

-

2494

.

10.

Eyre

TA

,

Walter

HS

,

Iyengar

S

, et al.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

.

Haematologica

.

2019

;

104

(

2

):

e68

-

e71

.

11.

Martin

P

,

Maddocks

K

,

Leonard

JP

, et al.

Postibrutinib outcomes in patients with mantle cell lymphoma

.

Blood

.

2016

;

127

(

12

):

1559

-

1563

.

12.

Zhao

X

,

Ren

Y

,

Lawlor

M

, et al.

BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models

.

Cancer Cell

.

2019

;

35

(

5

):

752

-

766.e9

.

13.

Chiron

D

,

Bellanger

C

,

Papin

A

, et al.

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

.

Blood

.

2016

;

128

(

24

):

2808

-

2818

.

14.

Thus

YJ

,

Eldering

E

,

Kater

AP

,

Spaargaren

M

.

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma

.

Leukemia

.

2022

;

36

(

9

):

2165

-

2176

.

15.

Chiron

D

,

Di Liberto

M

,

Martin

P

, et al.

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma overriding relapse-specific BTK mutation in MCL

.

Cancer Discov

.

2014

;

4

(

9

):

1022

-

1035

.

16.

Ondrisova

L

,

Mraz

M

.

Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies

.

Front Oncol

.

2020

;

10

:

591577

.

17.

Zhang

L

,

Yao

Y

,

Zhang

S

, et al.

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

.

Sci Transl Med

.

2019

;

11

(

491

):

eaau1167

.

18.

Chiron

D

,

Dousset

C

,

Brosseau

C

, et al.

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

.

Oncotarget

.

2015

;

6

(

11

):

8750

-

8759

.

19.

Le Gouill

S

,

Morschhauser

F

,

Chiron

D

, et al.

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

.

Blood

.

2021

;

137

(

7

):

877

-

887

.

20.

Decombis

S

,

Papin

A

,

Bellanger

C

, et al.

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition

.

Haematologica

.

2022

;

107

(

12

):

2905

-

2917

.

21.

Brohl

AS

,

Stinson

JR

,

Su

HC

, et al.

Germline CARD11 mutation in a patient with severe congenital B cell lymphocytosis

.

J Clin Immunol

.

2015

;

35

(

1

):

32

-

46

.

22.

Snow

AL

,

Xiao

W

,

Stinson

JR

, et al.

Congenital B cell lymphocytosis explained by novel germline CARD11 mutations

.

J Exp Med

.

2012

;

209

(

12

):

2247

-

2261

.

23.

Takeuchi

M

,

Rothe

M

,

Goeddel

DV

.

Anatomy of TRAF2: distinct domains for nuclear factor-κB activation and association with tumor necrosis factor signaling proteins

.

J Biol Chem

.

1996

;

271

(

33

):

19935

-

19942

.

24.

Lenz

G

,

Davis

RE

,

Ngo

VN

, et al.

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

.

Science

.

2008

;

319

(

5870

):

1676

-

1679

.

25.

Caeser

R

,

Walker

I

,

Gao

J

, et al.

Acquired CARD11 mutation promotes BCR independence in diffuse large B cell lymphoma

.

JCO Precis Oncol

.

2021

;

5

:

145

-

152

.

26.

Rahal

R

,

Frick

M

,

Romero

R

, et al.

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

.

Nat Med

.

2014

;

20

(

1

):

87

-

92

.

27.

Saba

NS

,

Liu

D

,

Herman

SE

, et al.

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma

.

Blood

.

2016

;

128

(

1

):

82

-

92

.

28.

Rauert-Wunderlich

H

,

Rudelius

M

,

Berberich

I

,

Rosenwald

A

.

CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma

.

Cell Death Dis

.

2018

;

9

(

2

). 86-9.

29.

Esteve-Arenys

A

,

Garcia-Valero

J

,

Gonzalez

D

, et al.

Pharmacological downregulation of BFL-1 by the BET bromodomain inhibitor CPI203 overcomes ABT-199 resistance in MYC+/BCL2+ double hit lymphoma

.

Cancer Res

.

2017

;

77

(

suppl 13

):

2161

.

30.

Haselager

MV

,

Kielbassa

K

,

Ter Burg

J

, et al.

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

.

Blood

.

2020

;

136

(

25

):

2918

-

2926

.

31.

Jenson

JM

,

Ryan

JA

,

Grant

RA

,

Letai

A

,

Keating

AE

.

Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1

.

Elife

.

2017

;

6

:

e25541

.

32.

Prazma

CM

,

Yazawa

N

,

Fujimoto

Y

,

Fujimoto

M

,

Tedder

TF

.

CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo

.

J Immunol

.

2007

;

179

(

7

):

4550

-

4562

.

33.

Seshadri

MR

,

Melnick

AM

.

Targeting MALT1 for the treatment of diffuse large B-cell lymphoma

.

Leuk Lymphoma

.

2022

;

63

(

4

):

789

-

798

.

34.

Quancard

J

,

Klein

T

,

Fung

S-Y

, et al.

An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient

.

Nat Chem Biol

.

2019

;

15

(

3

):

304

-

313

.

35.

Philippar

U

,

Lu

T

,

Vloemans

N

, et al.

Discovery of JNJ-67856633: a novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas

.

Cancer Res

.

2020

;

80

(

suppl 16

):

5690

.

36.

Miebach

L

,

Berner

J

,

Bekeschus

S

.

In ovo model in cancer research and tumor immunology

.

Front Immunol

.

2022

;

13

:

1006064

.

37.

Dobrovolsky

D

,

Wang

ES

,

Morrow

S

, et al.

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

.

Blood

.

2019

;

133

(

9

):

952

-

961

.

38.

Jain

P

,

Wang

ML

.

Mantle cell lymphoma in 2022—a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments

.

Am J Hematol

.

2022

;

97

(

5

):

638

-

656

.

39.

Phillips

T

,

Dickinson

M

,

Morschhauser

F

, et al.

Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL), most of whom had failed prior Bruton’s tyrosine kinase inhibitor (BTKi) therapy [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

130

.

40.

van der Horst

HJ

,

de Jonge

AV

,

Hiemstra

IH

, et al.

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

.

Blood Cancer J

.

2021

;

11

(

2

). 38-8.

41.

Balaji

S

,

Ahmed

M

,

Lorence

E

,

Yan

F

,

Nomie

K

,

Wang

M

.

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

.

J Hematol Oncol

.

2018

;

11

(

1

):

83

.

42.

Shaffer

AL

,

Phelan

JD

,

Wang

JQ

, et al.

Overcoming acquired epigenetic resistance to BTK inhibitors overcoming acquired epigenetic resistance to BTK inhibitors

.

Blood Cancer Discov

.

2021

;

2

(

6

):

630

-

647

.

43.

Ma

MCJ

,

Tadros

S

,

Bouska

A

, et al.

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

.

Haematologica

.

2022

;

107

(

3

):

690

-

701

.

44.

Bartlett

NL

,

Costello

BA

,

LaPlant

BR

, et al.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

.

Blood

.

2018

;

131

(

2

):

182

-

190

.

45.

Meitlis

I

,

Allenspach

EJ

,

Bauman

BM

, et al.

Multiplexed functional assessment of genetic variants in CARD11

.

Am J Hum Genet

.

2020

;

107

(

6

):

1029

-

1043

.

46.

Zhang

H

,

Nakauchi

Y

,

Köhnke

T

, et al.

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

.

Nat Cancer

.

2020

;

1

(

8

):

826

-

839

.

47.

Jiang

VC

,

Liu

Y

,

Lian

J

, et al.

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

.

J Clin Invest

.

2023

;

133

(

3

):

e165694

.

48.

Minderman

M

,

Lantermans

HC

,

Grüneberg

LJ

, et al.

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas

.

Blood Cancer J

.

2023

;

13

(

1

):

37

.

49.

Shah

SB

,

Carlson

CR

,

Lai

K

, et al.

Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas

.

Nat Mater

.

2023

;

22

(

4

):

511

-

523

.

50.

Dai

B

,

Grau

M

,

Juilland

M

, et al.

B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma

.

Blood

.

2017

;

129

(

3

):

333

-

346

.

51.

Pieters

T

,

T’Sas

S

,

Vanhee

S

, et al.

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice

.

J Exp Med

.

2021

;

218

(

10

):

e20202280

.

52.

Fontan

L

,

Hatcher

J

,

Scott

D

, et al.

Chemically induced degradation of MALT1 to treat B-cell lymphomas [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

2073

.

53.

Bertram

K

,

Leary

PJ

,

Boudesco

C

, et al.

Inhibitors of Bcl-2 and Bruton’s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models

.

Leukemia

.

2022

;

36

(

4

):

1035

-

1047

.